What is already known about this subject
- There is ongoing controversy regarding the association between
tacrolimus C0 or IPV and clinical outcomes after lung
transplantation.
- The impact of CYP3A5*3 genotype on C0 is
validated. Whether it affects IPV and clinical outcomes remains
controversial.
- Furthermore, the impact of C0/IPV combination on
clinical outcomes remains unexplored.